Preventing Recurrent Stroke in 2025: Clinical and Managed Care Perspectives
A Q&A With Andrew Russman, DO
A Q&A With Alpesh N. Amin, MD, MBA
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5